Physician profile
Christopher S Ray
NPI 1548267131
$17,724.74
in general payments reported to CMS, 2019-2025
26 companies · $2,438 in 2025
The $2,438 reported for 2025 was more than what 81% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $264 · 2021: $9,436 · 2022: $1,481 · 2023: $1,640 · 2024: $2,465 · 2025: $2,438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,578 · Travel and Lodging: $961 · Education: $4.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,578.25 |
| Travel and Lodging | $961.11 |
| Education | $4.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Titan Pharmaceuticals, INC. | $8,851.30 | 2020-2021 | |
| Abbott Laboratories | $3,760.91 | 2020-2025 | Proclaim, Eterna |
| Nalu Medical, INC. | $1,107.04 | 2024-2025 | Nalu Neurostimulation System |
| Vertos Medical, INC. | $804.03 | 2021-2024 | Mild Device Kit |
| Boston Scientific Corporation | $686.44 | 2021-2025 | General - Pain Management, Superion Indirect Decompression System, Intracept |
| Nevro Corp. | $675.55 | 2024 | Senza |
| Globus Medical, INC. | $486.16 | 2025 | Senza, Corridor, Omnia |
| Stryker Corporation | $325.63 | 2024-2025 | Spinejack, Mild Device Kit, Optablate |
| Foundation Fusion Solutions, LLC | $193.94 | 2024-2025 | |
| Saluda Medical Americas, INC. | $145.94 | 2025 | Evoke |
| Scilex Pharmaceuticals INC. | $131.09 | 2022-2023 | Ztlido |
| Medtronic, INC. | $109.26 | 2025 | Kyphon Express II Kyphopak Tray |
| Biohaven Pharmaceutical Holding Company LTD. | $75.26 | 2022 | |
| Pfizer INC. | $63.21 | 2023 | |
| Collegium Pharmaceutical, INC. | $61.57 | 2022-2023 | Xtampza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $45.88 | 2021 | |
| Tersera Therapeutics LLC | $29.18 | 2022 | |
| Bioventus LLC | $24.91 | 2023 | Durolane |
| Abbvie INC. | $24.34 | 2021 | |
| Zoll Respicardia, INC. | $22.08 | 2023 | Remede System |
| Ultragenyx Pharmaceutical INC. | $20.83 | 2021 | |
| Alkermes, INC. | $19.80 | 2020 | |
| Grt US Holding, INC. | $19.41 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.27 | 2024 | Relistor |
| Depuy Synthes Sales INC. | $14.06 | 2023 | Monovisc, Orthovisc |
| Itamar Medical INC | $10.65 | 2023 | Watchpatone |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.